DEXCOM INC
About DEXCOM INC
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $4.7B
- Net income
- $836.3M
- Total assets
- $6.3B
- Market cap
- $28.1B
- Gross margin
- 60.1%
- Operating margin
- 19.6%
- Net margin
- 17.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.7B
- Cost of revenue
- $1.9B
- Gross profit
- $2.8B
- Operating expenses
- $1.9B
- Operating income
- $911.8M
- Income tax
- $252.1M
- Net income
- $836.3M
- EPS (basic)
- $2.14
- EPS (diluted)
- $2.09
Balance sheet
- Total assets
- $6.3B
- Current assets
- $4.0B
- Total liabilities
- $3.6B
- Current liabilities
- $2.1B
- Shareholders’ equity
- $2.7B
Cash flow
- Operating cash flow
- $1.4B
- Investing cash flow
- $536.0M
- Financing cash flow
- -$1.7B
- Net cash flow
- $311.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $28.1B
- P/E ratio
- 36.7
- EPS (diluted)
- $2.09
- Shares outstanding
- 366.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 14, 2005
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $836.3M in FY2025.
- Revenue grew 90% from FY2021 to FY2025.
- Gross margin of 60.1%, net margin 17.9%.
- Trading 14% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 36.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review DEXCOM INC.
Write a review
News about DEXCOM INC
News & sentiment via Polygon.io
